Genentech to manufacture tocilizumab under contract
This article was originally published in Scrip
Genentechhas entered an agreement to manufacture bulk supplies of the anti-interleukin-6 receptor antibody Actemra (tocilizumab) forChugai, its sister company under the Roche umbrella. Chugai will continue to manufacture bulk quantities and formulate the product at a facility in Japan, which was originally expected to be able to meet global demand. Rather than invest in additional domestic capacity, a decision has taken to outsource production to Genentech's Vacaville site in California, Chugai said. Actemra is already marketed in Japan for arthritis and Castleman's disease and has just been recommended for approval in the US for rheumatoid arthritis.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: Bayer takes strategic steps to cut debt; AbbVie confirms internal appointment as CEO; another RIPK1 setback for Denali/Sanofi; new biotech reality in China; and ex-Daiichi Sankyo CEO shares insights into tough decisions.
In this week's podcast edition of Five Must-Know Things: the biggest drug launches expected in 2024; Roche’s Pharma CEO talks about growth momentum; 10 pivotal studies to look out for this year; the obesity market now and in future; and what does 2024 hold for transformative technology in biopharma.
In this week's podcast edition of Five Must-Know Things: Bayer’s pipeline refresh; J&J’s selective pharma M&A approach; silver lining for Gilead’s Trodelvy miss?; paying for obesity drugs; and the story behind Vertex and CRISPR’s gene therapy breakthrough.